Stem cells in liver failure
Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF m...
Gespeichert in:
| Veröffentlicht in: | Baillière's best practice & research. Clinical gastroenterology 2012-02, Vol.26 (1), p.35-45 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Baillière's best practice & research. Clinical gastroenterology |
| container_volume | 26 |
| creator | Russo, Francesco P., MD Parola, Maurizio, PhD |
| description | Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF mortality and the increasing worldwide prevalence of cirrhosis that, in turn, is the main predisposing cause for hepatocellular carcinoma (HCC). Moreover, in the next decade because an increased number of patients reaching end-stage disease and requiring OLT may face a shortage of donor livers. This clinical scenario led several laboratories to explore the feasibility and efficiency of alternative approaches, involving cellular therapy, to counteract liver failure. The present chapter overviews results and concepts emerged from recent experimental and clinical studies in which adult or embryonic hepatocytes, hepatic stem/progenitor cells, induced pluripotent stem (iPS) cells as well as extrahepatic stem cells have been used as putative transplantable cell sources. |
| doi_str_mv | 10.1016/j.bpg.2012.01.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_993102182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691812000029</els_id><sourcerecordid>1654686694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-f1337fd413ee5ac272ed27c94753bca654692b60f0b157ebfb7b50fefcddd9b83</originalsourceid><addsrcrecordid>eNp9kc1r3DAQxUVoaDbb_gGhUBZySC52NSNbtigUQsgXBHJIexaWPCraeu2tZAfy30dm8wE55KQ5_N4bzXuMHQHPgYP8sc7N9m-OHDDnkHMOe2wBpcAMFMhP84yQSQX1ATuMcc0TIZX6zA4QixpLLBbs2_1Im5Wlrosr3686_0Bh5RrfTYG-sH3XdJG-Pr9L9ufy4vf5dXZ7d3Vzfnab2ULWY-ZAiMq1BQiisrFYIbVYWVVUpTC2kWUhFRrJHTdQVmScqUzJHTnbtq0ytViyk53vNgz_J4qj3vg4f6npaZiiVkoAR6gxkacfkjAvq6VURUKP36HrYQp9ukMDF1iqSvB5NewoG4YYAzm9DX7ThMcE6TljvdYpYz1nrDnolGDSfH92nsyG2lfFS6gJ-LkDKIX24CnoaD31llofyI66HfyH9r_eqW3ne2-b7h89Uny7Qsek0fdzyXPHgKlfjko8AQicneQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032597308</pqid></control><display><type>article</type><title>Stem cells in liver failure</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Russo, Francesco P., MD ; Parola, Maurizio, PhD</creator><creatorcontrib>Russo, Francesco P., MD ; Parola, Maurizio, PhD</creatorcontrib><description>Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF mortality and the increasing worldwide prevalence of cirrhosis that, in turn, is the main predisposing cause for hepatocellular carcinoma (HCC). Moreover, in the next decade because an increased number of patients reaching end-stage disease and requiring OLT may face a shortage of donor livers. This clinical scenario led several laboratories to explore the feasibility and efficiency of alternative approaches, involving cellular therapy, to counteract liver failure. The present chapter overviews results and concepts emerged from recent experimental and clinical studies in which adult or embryonic hepatocytes, hepatic stem/progenitor cells, induced pluripotent stem (iPS) cells as well as extrahepatic stem cells have been used as putative transplantable cell sources.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1016/j.bpg.2012.01.001</identifier><identifier>PMID: 22482524</identifier><identifier>CODEN: BPRCB6</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Bone marrow ; Bone Marrow Transplantation ; Bone marrow-derived stem cells ; Cell Proliferation ; Cellular therapy ; Embryonic hepatocytes ; End Stage Liver Disease ; Gastroenterology and Hepatology ; Hepatic regenerative medicine ; Hepatic stem/progenitor cells ; Hepatocytes - physiology ; Hepatocytes - transplantation ; Humans ; Induced pluripotent stem cells ; Induced Pluripotent Stem Cells - physiology ; Induced Pluripotent Stem Cells - transplantation ; Liver cirrhosis ; Liver Cirrhosis - complications ; Liver Failure, Acute - surgery ; Liver Regeneration - physiology ; Stem Cell Transplantation - methods ; Stem cells ; Transplants & implants</subject><ispartof>Baillière's best practice & research. Clinical gastroenterology, 2012-02, Vol.26 (1), p.35-45</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-f1337fd413ee5ac272ed27c94753bca654692b60f0b157ebfb7b50fefcddd9b83</citedby><cites>FETCH-LOGICAL-c468t-f1337fd413ee5ac272ed27c94753bca654692b60f0b157ebfb7b50fefcddd9b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bpg.2012.01.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22482524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Russo, Francesco P., MD</creatorcontrib><creatorcontrib>Parola, Maurizio, PhD</creatorcontrib><title>Stem cells in liver failure</title><title>Baillière's best practice & research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF mortality and the increasing worldwide prevalence of cirrhosis that, in turn, is the main predisposing cause for hepatocellular carcinoma (HCC). Moreover, in the next decade because an increased number of patients reaching end-stage disease and requiring OLT may face a shortage of donor livers. This clinical scenario led several laboratories to explore the feasibility and efficiency of alternative approaches, involving cellular therapy, to counteract liver failure. The present chapter overviews results and concepts emerged from recent experimental and clinical studies in which adult or embryonic hepatocytes, hepatic stem/progenitor cells, induced pluripotent stem (iPS) cells as well as extrahepatic stem cells have been used as putative transplantable cell sources.</description><subject>Bone marrow</subject><subject>Bone Marrow Transplantation</subject><subject>Bone marrow-derived stem cells</subject><subject>Cell Proliferation</subject><subject>Cellular therapy</subject><subject>Embryonic hepatocytes</subject><subject>End Stage Liver Disease</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatic regenerative medicine</subject><subject>Hepatic stem/progenitor cells</subject><subject>Hepatocytes - physiology</subject><subject>Hepatocytes - transplantation</subject><subject>Humans</subject><subject>Induced pluripotent stem cells</subject><subject>Induced Pluripotent Stem Cells - physiology</subject><subject>Induced Pluripotent Stem Cells - transplantation</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Failure, Acute - surgery</subject><subject>Liver Regeneration - physiology</subject><subject>Stem Cell Transplantation - methods</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1r3DAQxUVoaDbb_gGhUBZySC52NSNbtigUQsgXBHJIexaWPCraeu2tZAfy30dm8wE55KQ5_N4bzXuMHQHPgYP8sc7N9m-OHDDnkHMOe2wBpcAMFMhP84yQSQX1ATuMcc0TIZX6zA4QixpLLBbs2_1Im5Wlrosr3686_0Bh5RrfTYG-sH3XdJG-Pr9L9ufy4vf5dXZ7d3Vzfnab2ULWY-ZAiMq1BQiisrFYIbVYWVVUpTC2kWUhFRrJHTdQVmScqUzJHTnbtq0ytViyk53vNgz_J4qj3vg4f6npaZiiVkoAR6gxkacfkjAvq6VURUKP36HrYQp9ukMDF1iqSvB5NewoG4YYAzm9DX7ThMcE6TljvdYpYz1nrDnolGDSfH92nsyG2lfFS6gJ-LkDKIX24CnoaD31llofyI66HfyH9r_eqW3ne2-b7h89Uny7Qsek0fdzyXPHgKlfjko8AQicneQ</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Russo, Francesco P., MD</creator><creator>Parola, Maurizio, PhD</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Stem cells in liver failure</title><author>Russo, Francesco P., MD ; Parola, Maurizio, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-f1337fd413ee5ac272ed27c94753bca654692b60f0b157ebfb7b50fefcddd9b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Bone marrow</topic><topic>Bone Marrow Transplantation</topic><topic>Bone marrow-derived stem cells</topic><topic>Cell Proliferation</topic><topic>Cellular therapy</topic><topic>Embryonic hepatocytes</topic><topic>End Stage Liver Disease</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatic regenerative medicine</topic><topic>Hepatic stem/progenitor cells</topic><topic>Hepatocytes - physiology</topic><topic>Hepatocytes - transplantation</topic><topic>Humans</topic><topic>Induced pluripotent stem cells</topic><topic>Induced Pluripotent Stem Cells - physiology</topic><topic>Induced Pluripotent Stem Cells - transplantation</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Failure, Acute - surgery</topic><topic>Liver Regeneration - physiology</topic><topic>Stem Cell Transplantation - methods</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Russo, Francesco P., MD</creatorcontrib><creatorcontrib>Parola, Maurizio, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Russo, Francesco P., MD</au><au>Parola, Maurizio, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stem cells in liver failure</atitle><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>26</volume><issue>1</issue><spage>35</spage><epage>45</epage><pages>35-45</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><coden>BPRCB6</coden><abstract>Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF mortality and the increasing worldwide prevalence of cirrhosis that, in turn, is the main predisposing cause for hepatocellular carcinoma (HCC). Moreover, in the next decade because an increased number of patients reaching end-stage disease and requiring OLT may face a shortage of donor livers. This clinical scenario led several laboratories to explore the feasibility and efficiency of alternative approaches, involving cellular therapy, to counteract liver failure. The present chapter overviews results and concepts emerged from recent experimental and clinical studies in which adult or embryonic hepatocytes, hepatic stem/progenitor cells, induced pluripotent stem (iPS) cells as well as extrahepatic stem cells have been used as putative transplantable cell sources.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>22482524</pmid><doi>10.1016/j.bpg.2012.01.001</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6918 |
| ispartof | Baillière's best practice & research. Clinical gastroenterology, 2012-02, Vol.26 (1), p.35-45 |
| issn | 1521-6918 1532-1916 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_993102182 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Bone marrow Bone Marrow Transplantation Bone marrow-derived stem cells Cell Proliferation Cellular therapy Embryonic hepatocytes End Stage Liver Disease Gastroenterology and Hepatology Hepatic regenerative medicine Hepatic stem/progenitor cells Hepatocytes - physiology Hepatocytes - transplantation Humans Induced pluripotent stem cells Induced Pluripotent Stem Cells - physiology Induced Pluripotent Stem Cells - transplantation Liver cirrhosis Liver Cirrhosis - complications Liver Failure, Acute - surgery Liver Regeneration - physiology Stem Cell Transplantation - methods Stem cells Transplants & implants |
| title | Stem cells in liver failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T21%3A20%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stem%20cells%20in%20liver%20failure&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=Russo,%20Francesco%20P.,%20MD&rft.date=2012-02-01&rft.volume=26&rft.issue=1&rft.spage=35&rft.epage=45&rft.pages=35-45&rft.issn=1521-6918&rft.eissn=1532-1916&rft.coden=BPRCB6&rft_id=info:doi/10.1016/j.bpg.2012.01.001&rft_dat=%3Cproquest_cross%3E1654686694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1032597308&rft_id=info:pmid/22482524&rft_els_id=S1521691812000029&rfr_iscdi=true |